Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00586430 · ClinicalTrials.gov registry record · NA
The Impact of Lorazepam on Cognition in APOE e4 Carriers
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT00586430: Completed NA study, sponsored by Mayo Clinic.
NCT00586430 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00586430, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
We expect the results of this pilot study to justify a larger study that follows people to determine if certain tests of memory and attention, performed while sleepiness is induced by a single dose of lorazepam (a widely used anti-anxiety medication) could predict an individual's risk of developing AD. We plan to compare cognitively normal people who possess a common gene that increases risk for AD- the apolipoprotein E (APOE) e4 allele-to individuals without this gene. We hypothesize that a single 2 mg dose of lorazepam will cause more cognitive impairment in carriers of the APOE e4 allele than in noncarriers, and that the carriers will recover more slowly from these impairments than noncarriers.
Interventions
- DRUG placebo
- DRUG lorazepam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00586430
The ClinicalTrials.gov registry entry for NCT00586430 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00586430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00586430 about?
NCT00586430 is a clinical study titled "The Impact of Lorazepam on Cognition in APOE e4 Carriers". We expect the results of this pilot study to justify a larger study that follows people to determine if certain tests of memory and attention, performed while sleepiness is induced by a single dose of lorazepam (a widely used anti-anxiety medication) could predict an individual's risk of developing ...
What is the current status of trial NCT00586430?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2005-12. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00586430?
The interventions under investigation include: placebo (DRUG), lorazepam (DRUG).
Who is sponsoring clinical trial NCT00586430?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.